Analysts forecast that AzurRx BioPharma Inc (NASDAQ:AZRX) will report earnings per share (EPS) of ($0.20) for the current quarter, Zacks reports. Zero analysts have issued estimates for AzurRx BioPharma’s earnings, with estimates ranging from ($0.21) to ($0.19). AzurRx BioPharma reported earnings per share of ($0.28) in the same quarter last year, which would suggest a positive year-over-year growth rate of 28.6%. The company is scheduled to issue its next earnings results on Monday, November 12th.
On average, analysts expect that AzurRx BioPharma will report full year earnings of ($0.87) per share for the current year, with EPS estimates ranging from ($0.91) to ($0.81). For the next financial year, analysts forecast that the company will report earnings of ($0.66) per share, with EPS estimates ranging from ($0.74) to ($0.51). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover AzurRx BioPharma.
Several equities research analysts have commented on AZRX shares. HC Wainwright set a $8.00 price objective on AzurRx BioPharma and gave the stock a “buy” rating in a research note on Tuesday, October 16th. Oppenheimer started coverage on AzurRx BioPharma in a research note on Wednesday, October 17th. They set an “outperform” rating and a $6.00 price objective for the company. ValuEngine upgraded AzurRx BioPharma from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, CIBC started coverage on AzurRx BioPharma in a research note on Wednesday, October 17th. They set an “outperform” rating and a $6.00 price objective for the company.
Large investors have recently bought and sold shares of the business. Opaleye Management Inc. acquired a new position in shares of AzurRx BioPharma during the 2nd quarter worth approximately $417,000. Ardsley Advisory Partners lifted its holdings in AzurRx BioPharma by 66.3% in the second quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock valued at $440,000 after acquiring an additional 54,697 shares during the last quarter. 683 Capital Management LLC acquired a new position in AzurRx BioPharma in the second quarter valued at approximately $1,284,000. Finally, Gilder Gagnon Howe & Co. LLC acquired a new position in AzurRx BioPharma in the second quarter valued at approximately $1,782,000. Institutional investors own 18.61% of the company’s stock.
NASDAQ:AZRX traded down $0.01 during trading hours on Friday, hitting $2.45. 47,747 shares of the stock were exchanged, compared to its average volume of 77,293. AzurRx BioPharma has a 52-week low of $2.10 and a 52-week high of $4.08.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.